{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:22:56Z","timestamp":1785468176116,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","award":["Postgraduate studies and Scientific Research Funding Sector"],"award-info":[{"award-number":["Postgraduate studies and Scientific Research Funding Sector"]}],"id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","award":["Postgraduate studies and Scientific Research Funding Sector"],"award-info":[{"award-number":["Postgraduate studies and Scientific Research Funding Sector"]}],"id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","award":["Postgraduate studies and Scientific Research Funding Sector"],"award-info":[{"award-number":["Postgraduate studies and Scientific Research Funding Sector"]}],"id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","award":["Postgraduate studies and Scientific Research Funding Sector"],"award-info":[{"award-number":["Postgraduate studies and Scientific Research Funding Sector"]}],"id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"publisher","award":["Postgraduate studies and Scientific Research Funding Sector"],"award-info":[{"award-number":["Postgraduate studies and Scientific Research Funding Sector"]}],"id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Renin\u2013angiotensin\u2013aldosterone system (RAAS) is hypothesized to be in the center of COVID pathophysiology as the angiotensin converting enzyme 2 (ACE2) represents the main entrance of the virus, thus there is a need to address the effect of chronic use of RAAS blockers, as in case of treatment of cardiovascular diseases, on the expression of ACE2. Accordingly, this study aimed to clarify the effect of ACE inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) on ACE2 and to assess the correlation between ACE2 and several anthropometric and clinic-pathological factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 40 healthy controls and 60 Egyptian patients suffering from chronic cardiovascular diseases were enrolled in this study. Patients were divided into 40 patients treated with ACEIs and 20 patients treated with ARBs. Serum ACE2 levels were assessed by ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Assessment of serum ACE2 level in different groups showed a significant difference between ACEIs and healthy groups and ACEIs and ARBs group, while there was no difference between ARBs and healthy. Multivariate analysis using ACE2 level as constant and age, female sex, ACEIs use and myocardial infarction (MI) showed that there was a significant effect of female sex and ACEIs use on ACE2 level with no effect of age, MI and diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ACE2 levels varied between ACEIs and ARBs. It tends to be lower in ACEIs group and there is a strong positive association between ACE2 level and the female sex. This needs to be considered in Future studies to further understand the relationship between gender, sex hormones and ACE2 level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Retrospectively registered ClinicalTrials.gov ID: NCT05418361 (June 2022).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s40360-023-00667-w","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T10:02:31Z","timestamp":1681466551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Sarah","family":"Farid fahmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Omar","family":"El Derany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Khorshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtehal","family":"El-Demerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"issue":"6","key":"667_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273\u201392. https:\/\/doi.org\/10.1111\/j.476-5381.2010.00750.x. PMID: 20590619; PMCID: PMC2938800.","journal-title":"Br J Pharmacol."},{"issue":"7","key":"667_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","volume":"11","author":"F Jiang","year":"2014","unstructured":"Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, et al. Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets. Nat Rev Cardiol. 2014;11(7):413\u201326.","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"667_CR3","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"667_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/0004563220928361","volume":"57","author":"AE Zemlin","year":"2020","unstructured":"Zemlin AE, Wiese OJ. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). Ann Clin Biochem. 2020;57(5):339\u201350. https:\/\/doi.org\/10.1177\/0004563220928361. Epub 2020 Jun 2. PMID: 32369402; PMCID: PMC7267743.","journal-title":"Ann Clin Biochem"},{"issue":"11","key":"667_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1042\/CS20200492","volume":"134","author":"K Lanza","year":"2020","unstructured":"Lanza K, Perez LG, Costa LB, Cordeiro TM, Palmeira VA, Ribeiro VT, et al. Covid-19: the renin-angiotensin system imbalance hypothesis. Clin Sci Lond. 2020;134(11):1259\u201364. https:\/\/doi.org\/10.1042\/CS20200492. PMID: 32507883; PMCID: PMC7276636.","journal-title":"Clin Sci Lond"},{"issue":"6","key":"667_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41440-020-0433-1","volume":"43","author":"G Li","year":"2020","unstructured":"Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI\/ARB of patients with COVID-19 complicated by hypertension. Hypertens Res. 2020;43(6):588\u201390.","journal-title":"Hypertens Res"},{"issue":"8","key":"667_CR7","doi-asserted-by":"publisher","first-page":"100618","DOI":"10.1016\/j.cpcardiol.2020.100618","volume":"45","author":"S Zaim","year":"2020","unstructured":"Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. Curr Probl Cardiol. 2020;45(8):100618.","journal-title":"Curr Probl Cardiol"},{"key":"667_CR8","doi-asserted-by":"publisher","first-page":"104906","DOI":"10.1016\/j.phrs.2020.104906","volume":"158","author":"M Tadic","year":"2020","unstructured":"Tadic M, Cuspidi C, Mancia G, Dell\u2019Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacol Res. 2020;158:104906.","journal-title":"Pharmacol Res"},{"key":"667_CR9","doi-asserted-by":"publisher","first-page":"107628","DOI":"10.1016\/j.pharmthera.2020.107628","volume":"215","author":"JJ Wang","year":"2020","unstructured":"Wang JJ, Edin ML, Zeldin DC, Li C, Wang DW, Chen C. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Pharmacol Ther. 2020;215:107628.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"667_CR10","doi-asserted-by":"publisher","first-page":"147032031666843","DOI":"10.1177\/1470320316668435","volume":"17","author":"K \u00dari","year":"2016","unstructured":"\u00dari K, Fagyas M, Kert\u00e9sz A, Borb\u00e9ly A, Jenei C, Bene O, et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst. 2016;17(4):1470320316668435 PMID:27965422;PMCID:PMC5843890.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"10","key":"667_CR11","doi-asserted-by":"publisher","first-page":"e1008235","DOI":"10.1371\/journal.pcbi.1008235","volume":"16","author":"M Sadria","year":"2020","unstructured":"Sadria M, Layton AT. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers during the COVID-19 pandemic: a modeling analysis. PLoS Comput Biol. 2020;16(10):e1008235. https:\/\/doi.org\/10.1371\/journal.pcbi.1008235. PMID: 33031368; PMCID: PMC7575117.","journal-title":"PLoS Comput Biol"},{"key":"667_CR12","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.2147\/JIR.S315981","volume":"14","author":"J Gu","year":"2021","unstructured":"Gu J, Yin J, Zhang M, Li J, Wu Y, Chen J, et al. Study on the Clinical Significance of ACE2 and Its Age-Related Expression. J Inflamm Res. 2021;14:2873\u201382.","journal-title":"J Inflamm Res"},{"key":"667_CR13","doi-asserted-by":"publisher","unstructured":"Gon\u00e7alves J, Santos CD, Fresco P, Fernandez-Llimos F. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. Rev Port Cardiol 2023;S0870\u20132551(23)00119\u20131. https:\/\/doi.org\/10.1016\/j.repc.2022.02.014. Epub ahead of print. PMID: 36893838; PMCID: PMC9999244.","DOI":"10.1016\/j.repc.2022.02.014"},{"issue":"2","key":"667_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11357-020-00314-w","volume":"43","author":"M AlGhatrif","year":"2021","unstructured":"AlGhatrif M, Tanaka T, Moore AZ, Bandinelli S, Lakatta EG, Ferrucci L. Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study. GeroScience. 2021;43(2):619\u201327.","journal-title":"GeroScience"},{"issue":"20","key":"667_CR15","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605\u201310.","journal-title":"Circulation"},{"issue":"1","key":"667_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpu086","volume":"28","author":"MMN Furuhashi","year":"2015","unstructured":"Furuhashi MMN, Mita T, Fuseya T, Ishimura S, Ohno K, Shibata S, Tanaka M, Watanabe Y, Akasaka H, Ohnishi H, Yoshida H, Takizawa H, Saitoh S, Ura N, Shimamoto K, Miura T. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28(1):15\u201321. https:\/\/doi.org\/10.1093\/ajh\/hpu086. Epub 2014 May 18 PMID: 24842388.","journal-title":"Am J Hypertens"},{"issue":"2","key":"667_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ehf2.13249","volume":"8","author":"T Zimmermann","year":"2021","unstructured":"Zimmermann T, Walter JE, Lopez-Ayala P, Strebel I, Amrein M, Koechlin M, et al. Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2. ESC heart failure. 2021;8(2):1717\u201321.","journal-title":"ESC heart failure"},{"issue":"19","key":"667_CR18","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","volume":"41","author":"IE Sama","year":"2020","unstructured":"Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020;41(19):1810\u20137.","journal-title":"Eur Heart J"},{"issue":"10","key":"667_CR19","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1097\/00004872-200410000-00020","volume":"22","author":"DJ Campbell","year":"2004","unstructured":"Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens. 2004;22(10):1971\u20136.","journal-title":"J Hypertens"},{"issue":"8","key":"667_CR20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/europace\/euw246","volume":"19","author":"TE Walters","year":"2017","unstructured":"Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2017;19(8):1280\u20137. https:\/\/doi.org\/10.1093\/europace\/euw246. PMID: 27738071.","journal-title":"Europace"},{"issue":"5","key":"667_CR21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/HYPERTENSIONAHA.120.15829","volume":"76","author":"JA Chirinos","year":"2020","unstructured":"Chirinos JA, Cohen JB, Zhao L, Hanff T, Sweitzer N, Fang J, et al. Clinical and proteomic correlates of plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. Hypertension. 2020;76(5):1526\u201336.","journal-title":"Hypertension"},{"issue":"23","key":"667_CR22","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1001\/jama.2020.8707","volume":"323","author":"S Bunyavanich","year":"2020","unstructured":"Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427\u20139. https:\/\/doi.org\/10.1001\/jama.2020.8707. PMID: 32432657; PMCID: PMC7240631.","journal-title":"JAMA."},{"issue":"11","key":"667_CR23","doi-asserted-by":"publisher","first-page":"10087","DOI":"10.18632\/aging.103415","volume":"12","author":"RPE Asselta","year":"2020","unstructured":"Asselta RPE, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging. 2020;12(11):10087\u201398.","journal-title":"Aging"},{"issue":"2","key":"667_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/ndt\/gfl632","volume":"22","author":"SSA Keidar","year":"2007","unstructured":"Keidar SSA, Raz A, Gamliel-Lazarovich A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrol Dial Transplant. 2007;22(2):597\u2013601. https:\/\/doi.org\/10.1093\/ndt\/gfl632. Epub 2006 Nov 9 PMID: 17095582.","journal-title":"Nephrol Dial Transplant"},{"key":"667_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jacc.2008.02.088","volume":"52","author":"S Epelman","year":"2008","unstructured":"Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J Am Coll Cardiol. 2008;52:750\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2008.02.088.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"667_CR26","doi-asserted-by":"publisher","first-page":"e61695","DOI":"10.1371\/journal.pone.0061695","volume":"8","author":"JT Ortiz-P\u00e9rez","year":"2013","unstructured":"Ortiz-P\u00e9rez JT, Riera M, Bosch X, De Caralt TM, Perea RJ, Pascual J, et al. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS One. 2013;8(4):e61695. https:\/\/doi.org\/10.1371\/journal.pone.0061695. PMID: 23630610; PMCID.","journal-title":"PLoS One"},{"issue":"6","key":"667_CR27","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3892\/etm.2014.1640","volume":"7","author":"M Wang","year":"2014","unstructured":"Wang M, Zhang W, Zhou Y, Zhou X. Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting. Exp Ther Med. 2014;7(6):1721\u20137. https:\/\/doi.org\/10.3892\/etm.2014.1640. Epub 2014 Mar 27. PMID: 24926374; PMCID: PMC4043627.","journal-title":"Exp Ther Med."},{"key":"667_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40842-017-0044-1","volume":"3","author":"M Soto","year":"2017","unstructured":"Soto M, Bang SI, McCombs J, Rodgers KE. Renin angiotensin system-modifying therapies are associated with improved pulmonary health. Clin Diabetes Endocrinol. 2017;3:6. https:\/\/doi.org\/10.1186\/s40842-017-0044-1.","journal-title":"Clin Diabetes Endocrinol"},{"key":"667_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/08998280.2018.1499293","volume":"31","author":"C Henry","year":"2018","unstructured":"Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018;31:419\u201323. https:\/\/doi.org\/10.1080\/08998280.2018.1499293.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"667_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1440-1681.2007.04797.x","volume":"35","author":"E El-Demerdash","year":"2008","unstructured":"El-Demerdash E, Salam OM, El-Batran SA, Abdallah HM, Shaffie NM. Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats. Clin Exp Pharmacol Physiol. 2008;35(2):159\u201367. https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04797.x.","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00667-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T10:09:20Z","timestamp":1681466960000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00667-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00667-w","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects were informed about the study investigations, study protocol, potential risks, purpose and benefits of the study and a written consent was signed by all enrolled subjects. This study conforms with the principles outlined in the Declaration of Helsinki and was approved by the Ethical Committee of Faculty of Medicine (FWA 000017585) Ain Shams University, Cairo, Egypt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}